Immune-related saliva micro-RNA’s to predict clinical response to a combination of cetuximab and low-dose chemotherapy in head and neck cancer (HNSCC) patients (pts) with poor performance status (PS).

A change in Medicare reimbursement for a prosthetic device that allows people who have had their voice box removed to speak has led some providers to stop offering the device or reducing the number of ...